We’re excited to share that Etcembly's collaboration with Avigen has been a resounding success!

This joint study brought together Etcembly’s AI‑designed multi‑specific T cell engagers and Avigen’s cutting‑edge microfluidic avidity platform. It's success marks another step forward in validating AI‑engineered biologics under dynamic, live‑cell conditions.  Our collaboration combined EMLy™‑powered molecular design with Avigen’s high‑resolution avidity readouts. Together we generated meaningful comparative insights across our bi‑ and tri‑specific constructs. Learn more about the Etcembly and Avigen collaboration here >